Drugs / LBEC0101
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01725620 | Nov 2012 → Apr 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02715908 | Apr 2016 → Dec 2017 | rheumatoid arthritis | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02357069 | Feb 2015 → Dec 2016 | rheumatoid arthritis | LG Life Sciences | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBEC0101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02715908 ↗ |
| Known as | etanercept | “BACKGROUND: To evaluate the long-term efficacy, safety and immunogenicity of continuing LBEC0101; the etanercept (ETN) biosimilar; or switching from the ETN reference product...” PMID 31113455 ↗ May 20191“LBEC0101 (Etanercept 25mg)” NCT01725620 ↗ |
| Modality | Protein / enzyme biologic | “LBEC0101 (etanercept biosimilar)” PMID 29259050 ↗ Dec 2017 |
| Route | Subcutaneous | “a single dose of LBEC0101 or Enbrel® was subcutaneously injected at 25 mg” PMID 28551775 ↗ Aug 2017 |